

Table IV-22

FEMALE BREAST CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	243,521	99.4%	203,930	99.4%	21,379	99.2%	15,729	99.3%	827	98.8%	21,211	99.1%
Epidermoid carcinoma ^c (8051-8131)	160	0.1%	127	0.1%	28	0.1%	-	-	-	-	-	-
Adenocarcinoma ^d	237,816	97.1%	199,514	97.3%	20,464	95.0%	15,430	97.4%	812	97.0%	20,563	96.1%
Adenocarcinoma, NOS (8140)	2,593	1.1%	2,087	1.0%	330	1.5%	132	0.8%	-	-	239	1.1%
Infiltrating duct carcinoma (8500)	165,691	67.6%	137,215	66.9%	15,162	70.4%	11,605	73.3%	610	72.9%	14,803	69.2%
Lobular carcinoma, NOS (8520)	19,630	8.0%	17,561	8.6%	1,195	5.5%	694	4.4%	54	6.5%	1,329	6.2%
Inflammatory adenocarcinoma (8530)	2,357	1.0%	1,941	0.9%	300	1.4%	95	0.6%	-	-	333	1.6%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	30,612	12.5%	26,664	13.0%	2,034	9.4%	1,637	10.3%	91	10.9%	2,484	11.6%
Mucinous adenocarcinoma (8480,8482)	6,197	2.5%	5,081	2.5%	507	2.4%	551	3.5%	20	2.4%	488	2.3%
Mucin-producing adenocarcinoma (8481)	135	0.1%	112	0.1%	19	0.1%	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	3,798	1.6%	3,454	1.7%	149	0.7%	152	1.0%	-	-	194	0.9%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,492	0.6%	1,094	0.5%	227	1.1%	152	1.0%	-	-	155	0.7%
Paget disease (8540-8543)	1,470	0.6%	1,211	0.6%	135	0.6%	108	0.7%	-	-	170	0.8%
Other adenocarcinomas ^e	3,841	1.6%	3,094	1.5%	406	1.9%	300	1.9%	-	-	362	1.7%
Other specific carcinomas ^f	2,795	1.1%	2,102	1.0%	521	2.4%	152	1.0%	-	-	352	1.6%
Medullary adenocarcinoma (8510-8513)	1,656	0.7%	1,154	0.6%	384	1.8%	104	0.7%	-	-	244	1.1%
Other ^g	1,139	0.5%	948	0.5%	137	0.6%	48	0.3%	-	-	108	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	2,750	1.1%	2,187	1.1%	366	1.7%	144	0.9%	-	-	282	1.3%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^d Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^e Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^g Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

Table IV-22 - continued

FEMALE BREAST CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	309	0.1%	252	0.1%	32	0.1%	17	0.1%	-	-	21	0.1%
Hemangiosarcomas (9120-9126,9170)	139	0.1%	124	0.1%	-	-	-	-	-	-	-	-
Other sarcomas ^c	170	0.1%	128	0.1%	25	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	673	0.3%	509	0.2%	73	0.3%	75	0.5%	-	-	114	0.5%
Phyllodes tumor, malignant (9020)	568	0.2%	428	0.2%	60	0.3%	66	0.4%	-	-	101	0.5%
Other ^d	105	0.0%	81	0.0%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	491	0.2%	381	0.2%	67	0.3%	20	0.1%	-	-	56	0.3%
Total ^e	244,994	100.0%	205,072	100.0%	21,551	100.0%	15,841	100.0%	837	100.0%	21,402	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^d Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^e Total includes carcinoma cases from the previous page.

Table IV-23

FEMALE BREAST CANCER(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^c	55,059	95.3%	45,326	95.2%	4,628	95.7%	4,341	94.7%	155	95.7%	4,316	96.1%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	20	0.0%	19	0.0%	-	-	-	-	-	-	-	-
Cribiform carcinoma <i>in situ</i> (8201/2)	4,639	8.0%	3,762	7.9%	344	7.1%	479	10.4%	-	-	356	7.9%
Ductal carcinoma <i>in situ</i> (8500/2)	20,452	35.4%	16,803	35.3%	1,781	36.8%	1,613	35.2%	64	39.5%	1,606	35.8%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	6,599	11.4%	5,803	12.2%	398	8.2%	213	4.6%	20	12.3%	472	10.5%
Comedocarcinoma <i>in situ</i> (8501/2)	5,378	9.3%	4,512	9.5%	405	8.4%	407	8.9%	-	-	394	8.8%
Intraductal and lobular carcinoma <i>in situ</i> (8522/2,8523/2,8524/2)	13,750	23.8%	11,087	23.3%	1,238	25.6%	1,286	28.1%	33	20.4%	1,161	25.9%
Intraductal micropapillary (8507/2)	1,935	3.3%	1,581	3.3%	196	4.1%	127	2.8%	-	-	165	3.7%
Other adenocarcinomas ^d	2,286	4.0%	1,759	3.7%	266	5.5%	215	4.7%	-	-	161	3.6%
Other <i>in situ</i> histologies ^e	2,737	4.7%	2,262	4.8%	210	4.3%	243	5.3%	-	-	175	3.9%
Total	57,796	100.0%	47,588	100.0%	4,838	100.0%	4,584	100.0%	162	100.0%	4,491	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8490, 8502-8506, 8514, 8521, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^e Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

Table V-13

CERVIX UTERI CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,756	98.5%	12,017	98.5%	2,058	98.5%	1,409	98.7%	81	100.0%	3,670	98.9%
Epidermoid carcinoma ^c	11,095	69.4%	8,315	68.2%	1,635	78.2%	956	66.9%	58	71.6%	2,712	73.1%
(8050-8131)												
Squamous cell carcinoma	7,033	44.0%	5,207	42.7%	1,143	54.7%	573	40.1%	37	45.7%	1,547	41.7%
(8070)												
Squamous cell,	1,288	8.1%	974	8.0%	196	9.4%	100	7.0%	-	-	385	10.4%
keratinizing (8071)												
Squamous cell,	1,600	10.0%	1,249	10.2%	173	8.3%	155	10.9%	-	-	445	12.0%
non-keratinizing (8072)												
Squamous cell,	945	5.9%	729	6.0%	87	4.2%	96	6.7%	-	-	274	7.4%
Microinvasive (8076)												
Other (8050-8069,	229	1.4%	156	1.3%	36	1.7%	32	2.2%	-	-	61	1.6%
8073-8075,8077-8131)												
Adenocarcinoma	3,941	24.6%	3,173	26.0%	321	15.4%	379	26.5%	16	19.8%	817	22.0%
(8140-8147,8160-8162,												
8180-8221,8250-8507,8514,												
8520-8551,8560,8570-8574,												
8576,8940-8941)												
Adenocarcinoma, NOS	2,031	12.7%	1,646	13.5%	148	7.1%	194	13.6%	-	-	425	11.4%
(8140)												
Adenosquamous (8560,8570)	693	4.3%	542	4.4%	75	3.6%	71	5.0%	-	-	171	4.6%
Other adenocarcinomas	1,217	7.6%	985	8.1%	98	4.7%	114	8.0%	-	-	221	6.0%
(8141-8147,8160-8162,												
8180-8221,8250-8507,												
8514,8520-8551,												
8571-8574,8576,												
8940-8941)												
Other specific carcinomas	266	1.7%	189	1.5%	30	1.4%	43	3.0%	-	-	54	1.5%
(8012-8015,8030-8046,												
8150-8155,8170-8175,												
8230-8249,8508,8510-8513,												
8561-8562,8575,8580-8671)												
Unspecified, Carcinoma, NOS	454	2.8%	340	2.8%	72	3.4%	31	2.2%	-	-	87	2.3%
(8010-8011)												

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

Table V-13 - continued

CERVIX UTERI CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	58	0.4%	47	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	120	0.8%	90	0.7%	17	0.8%	-	-	-	-	17	0.5%
Unspecified (8000-8005)	60	0.4%	46	0.4%	-	-	-	-	-	-	-	-
Total ^c	15,994	100.0%	12,200	100.0%	2,090	100.0%	1,428	100.0%	81	100.0%	3,712	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Total includes carcinoma cases from the previous page.

Table VI-24

COLON AND RECTUM CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	174,308	99.5%	143,336	99.5%	17,283	99.5%	11,673	99.6%	755	99.5%	13,988	99.5%
Epidermoid carcinoma ^c	708	0.4%	600	0.4%	87	0.5%	-	-	-	-	69	0.5%
(8051-8131)												
Squamous cell carcinoma	640	0.4%	540	0.4%	82	0.5%	-	-	-	-	58	0.4%
(8070-8078,8083-8084)												
Adenocarcinoma	166,422	95.0%	137,511	95.5%	16,133	92.9%	11,061	94.4%	703	92.6%	13,149	93.5%
(8050,8140-8147,												
8160-8162,8180-8221,												
8250-8507,8520-8551,8560,												
8570-8574,8576,8940-8941)												
Adenocarcinoma, NOS	114,780	65.5%	94,450	65.6%	11,310	65.1%	7,938	67.7%	532	70.1%	9,027	64.2%
(8140)												
Adenocarcinoma in	10,943	6.2%	8,958	6.2%	943	5.4%	853	7.3%	38	5.0%	805	5.7%
adenomatous polyp (8210)												
Adenocarcinoma in	5,801	3.3%	4,852	3.4%	552	3.2%	325	2.8%	-	-	526	3.7%
villous adenoma (8261)												
Mucinous adenocarcinoma	13,393	7.6%	11,392	7.9%	1,158	6.7%	744	6.3%	53	7.0%	1,149	8.2%
(8470-8473,8480,8482)												
Mucin-producing	4,859	2.8%	4,005	2.8%	600	3.5%	229	2.0%	-	-	368	2.6%
adenocarcinoma (8481)												
Signet ring	2,022	1.2%	1,714	1.2%	159	0.9%	129	1.1%	-	-	168	1.2%
adenocarcinoma (8490)												
Other adenocarcinomas ^d	14,624	8.4%	12,140	8.4%	1,411	8.1%	843	7.2%	44	5.8%	1,106	7.9%
Other specific carcinomas	5,554	3.2%	3,894	2.7%	882	5.1%	512	4.4%	46	6.1%	619	4.4%
(8012-8015,8030-8046,												
8150-8155,8170-8175,												
8230-8249,8508,8510-8513,												
8561-8562,8575,8580-8671)												
Neuroendocrine carcinoid	4,675	2.7%	3,153	2.2%	800	4.6%	466	4.0%	41	5.4%	545	3.9%
(8240-8245)												
Other ^e	879	0.5%	741	0.5%	82	0.5%	46	0.4%	-	-	74	0.5%
Unspecified, Carcinoma, NOS	1,624	0.9%	1,331	0.9%	181	1.0%	92	0.8%	-	-	151	1.1%
(8010-8011, 8020-8022)												

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a - Statistic not shown due to fewer than 16 cases during the time period.

^b - Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^c - Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^d - Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e - Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^e - Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

Table VI-24 - continued

COLON AND RECTUM CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	101	0.1%	77	0.1%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	224	0.1%	181	0.1%	20	0.1%	22	0.2%	-	-	22	0.2%
Unspecified (8000-8005)	504	0.3%	420	0.3%	53	0.3%	20	0.2%	-	-	39	0.3%
Total ^c	175,137	100.0%	144,014	100.0%	17,369	100.0%	11,722	100.0%	759	100.0%	14,057	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Total includes carcinoma cases from the previous page.

Table VIII-17

ESOPHAGUS CANCER (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	15,493	99.1%	12,978	99.1%	1,709	99.5%	668	99.3%	68	100.0%	1,023	99.0%
Epidermoid carcinoma ^c	5,926	37.9%	3,974	30.3%	1,413	82.3%	482	71.6%	35	51.5%	449	43.5%
(8051-8131)												
Squamous cell carcinoma	5,906	37.8%	3,956	30.2%	1,412	82.2%	481	71.5%	35	51.5%	447	43.3%
(8070-8078, 8083-8084)												
Adenocarcinoma	8,676	55.5%	8,253	63.0%	205	11.9%	150	22.3%	26	38.2%	525	50.8%
(8050,8140-8147,8160-8162, 8180-8221,8250-8507,8514, 8520-8551,8560,8570-8574, 8576,8940-8941)												
Other specific carcinomas	245	1.6%	200	1.5%	24	1.4%	17	2.5%	-	-	-	-
(8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)												
Unspecified, Carcinoma, NOS	646	4.1%	551	4.2%	67	3.9%	19	2.8%	-	-	36	3.5%
(8010-8011,8020-8022)												
Other specific types ^d	49	0.3%	41	0.3%	-	-	-	-	-	-	-	-
(8680-8713,8720-8790, 8800-8921,8930-8936, 8950-9030,9040-9044, 9060-9110,9120-9136, 9150-9252,9260-9365, 9370-9373,9380-9539, 9540-9582)												
Unspecified (8000-8005)	86	0.6%	80	0.6%	-	-	-	-	-	-	-	-
Total	15,628	100.0%	13,099	100.0%	1,717	100.0%	673	100.0%	68	100.0%	1,033	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^d Other specific types includes sarcomas and other soft tissue tumors.

Table XIV-17

LIVER AND INTRAHEPATIC BILE DUCT CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	15,824	96.9%	10,880	96.6%	1,832	98.0%	2,908	97.5%	110	93.2%	2,494	96.3%
Epidermoid carcinoma ^c (8170-8175)	12,402	76.0%	8,243	73.2%	1,527	81.7%	2,464	82.6%	92	78.0%	2,020	78.0%
Cholangiocarcinoma (8050,8140-8141, 8160-8161,8260,8440, 8480-8500,8570-8572)	2,407	14.7%	1,905	16.9%	193	10.3%	289	9.7%	-	-	330	12.7%
Intrahepatic cholangio- carcinoma (8160)	1,604	9.8%	1,264	11.2%	120	6.4%	203	6.8%	-	-	217	8.4%
Other (8050,8140-8141,8161, 8260,8440,8480-8500, 8570-8572)	803	4.9%	641	5.7%	73	3.9%	86	2.9%	-	-	113	4.4%
Other specific carcinomas ^d	368	2.3%	282	2.5%	44	2.4%	35	1.2%	-	-	42	1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	323	2.0%	232	2.1%	36	1.9%	51	1.7%	-	-	45	1.7%
Hepatoblastoma (8970)	167	1.0%	133	1.2%	-	-	18	0.6%	-	-	51	2.0%
Sarcoma ^e	158	1.0%	122	1.1%	-	-	26	0.9%	-	-	-	-
Haemangiosarcoma (9120-9133,9161)	102	0.6%	82	0.7%	-	-	16	0.5%	-	-	-	-
Other sarcomas ^f	56	0.3%	40	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8969,8971-9030, 9060-9110,9260-9365,9380-9539)	42	0.3%	33	0.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	132	0.8%	90	0.8%	16	0.9%	24	0.8%	-	-	19	0.7%
Total ^c	16,323	100.0%	11,258	100.0%	1,870	100.0%	2,983	100.0%	118	100.0%	2,591	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

^a - Statistic not shown due to fewer than 16 cases during the time period.

^b - Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^c - Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d - Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^e - Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f - Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8177-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e - Sarcoma includes histologies 8680-8713, 8800-8921, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f - Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9135-9136, 9150-9160, 9170-9252, 9370-9373, 9540-9582.

Table XV-23

LUNG AND BRONCHUS CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	197,475	98.9%	166,274	98.9%	19,817	98.9%	10,134	99.2%	674	99.1%	9,986	98.7%
Small cell (8041-8045)	28,313	14.2%	25,040	14.9%	2,175	10.9%	900	8.8%	129	19.0%	1,248	12.3%
Non-small cell ^c	169,162	84.7%	141,234	84.0%	17,642	88.1%	9,234	90.4%	545	80.1%	8,738	86.3%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	40,195	20.1%	33,640	20.0%	4,649	23.2%	1,638	16.0%	156	22.9%	1,812	17.9%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	72,983	36.6%	60,965	36.3%	6,827	34.1%	4,812	47.1%	168	24.7%	3,959	39.1%
Large cell (8011-8015)	7,866	3.9%	6,508	3.9%	961	4.8%	355	3.5%	23	3.4%	410	4.1%
Other non-small cell ^d	48,118	24.1%	40,121	23.9%	5,205	26.0%	2,429	23.8%	198	29.1%	2,557	25.3%
Sarcoma	334	0.2%	283	0.2%	30	0.1%	-	-	-	-	27	0.3%
(8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)												
Other specified types ^e	172	0.1%	144	0.1%	21	0.1%	-	-	-	-	-	-
(8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)												
Unspecified (8000-8005)	1,634	0.8%	1,403	0.8%	163	0.8%	59	0.6%	-	-	94	0.9%
Total	199,616	100.0%	168,105	100.0%	20,031	100.0%	10,215	100.0%	680	100.0%	10,121	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^d Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^e Other specific types includes melanomas.

Table XV-24

LUNG AND BRONCHUS CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Males by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	107,240	98.9%	88,996	98.9%	11,547	99.0%	6,023	99.2%	355	99.2%	5,649	98.7%
Small cell (8041-8045)	14,292	13.2%	12,468	13.9%	1,129	9.7%	605	10.0%	57	15.9%	697	12.2%
Non-small cell ^c	92,948	85.8%	76,528	85.1%	10,418	89.3%	5,418	89.3%	298	83.2%	4,952	86.5%
Squamous and transitional cell (8051-8052,8070-8084, 8120-8131)	25,834	23.8%	21,341	23.7%	3,108	26.6%	1,211	20.0%	97	27.1%	1,200	21.0%
Adenocarcinoma (8050,8140-8149, 8160-8162,8190-8221, 8250-8263,8270-8280, 8290-8337,8350-8390, 8400-8560,8570-8576, 8940-8941)	36,124	33.3%	29,847	33.2%	3,634	31.2%	2,452	40.4%	82	22.9%	2,016	35.2%
Large cell (8011-8015)	4,497	4.1%	3,675	4.1%	571	4.9%	233	3.8%	-	-	267	4.7%
Other non-small cell ^d	26,493	24.4%	21,665	24.1%	3,105	26.6%	1,522	25.1%	109	30.4%	1,469	25.7%
Sarcoma	199	0.2%	166	0.2%	21	0.2%	-	-	-	-	16	0.3%
(8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)												
Other specified types ^e	91	0.1%	77	0.1%	-	-	-	-	-	-	-	-
(8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)												
Unspecified (8000-8005)	858	0.8%	732	0.8%	88	0.8%	33	0.5%	-	-	52	0.9%
Total	108,389	100.0%	89,972	100.0%	11,665	100.0%	6,069	100.0%	358	100.0%	5,722	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^d Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^e Other specific types includes melanomas.

Table XV-25

LUNG AND BRONCHUS CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	90,235	98.9%	77,278	98.9%	8,270	98.9%	4,111	99.2%	319	99.1%	4,337	98.6%
Small cell (8041-8045)	14,021	15.4%	12,572	16.1%	1,046	12.5%	295	7.1%	72	22.4%	551	12.5%
Non-small cell ^c	76,214	83.5%	64,706	82.8%	7,224	86.3%	3,816	92.0%	247	76.7%	3,786	86.1%
Squamous and transitional cell (8051-8052,8070-8084,8120-8131)	14,361	15.7%	12,299	15.7%	1,541	18.4%	427	10.3%	59	18.3%	612	13.9%
Adenocarcinoma (8050,8140-8149,8160-8162,8190-8221,8250-8263,8270-8280,8290-8337,8350-8390,8400-8560,8570-8576,8940-8941)	36,859	40.4%	31,118	39.8%	3,193	38.2%	2,360	56.9%	86	26.7%	1,943	44.2%
Large cell (8011-8015)	3,369	3.7%	2,833	3.6%	390	4.7%	122	2.9%	-	-	143	3.3%
Other non-small cell ^d	21,625	23.7%	18,456	23.6%	2,100	25.1%	907	21.9%	89	27.6%	1,088	24.7%
Sarcoma (8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582)	135	0.1%	117	0.1%	-	-	-	-	-	-	-	-
Other specified types ^e (8720-8790,8930-8936,8950-8983,9000-9030,9060-9110,9260-9365,9380-9539)	81	0.1%	67	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	776	0.9%	671	0.9%	75	0.9%	26	0.6%	-	-	42	1.0%
Total	91,227	100.0%	78,133	100.0%	8,366	100.0%	4,146	100.0%	322	100.0%	4,399	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^d Includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas (8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671).

^e Other specific types includes melanomas.

Table XXI-13

OVARY CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma												
Epidermoid carcinoma ^c (8051-8131)	180	0.7%	135	0.6%	-	-	29	1.8%	-	-	25	1.0%
Adenocarcinoma ^d	20,802	85.1%	17,919	85.7%	1,303	79.3%	1,395	84.9%	83	79.8%	2,018	77.6%
Adenocarcinoma, NOS (8140)	3,279	13.4%	2,777	13.3%	308	18.7%	165	10.0%	-	-	331	12.7%
Papillary adenocarcinoma, NOS (8050,8260)	797	3.3%	673	3.2%	82	5.0%	37	2.3%	-	-	61	2.3%
Clear cell adenocarcinoma (8310,9110)	1,204	4.9%	987	4.7%	41	2.5%	163	9.9%	-	-	113	4.3%
Endometrioid carcinoma (8380-8383,8570)	2,717	11.1%	2,301	11.0%	131	8.0%	255	15.5%	-	-	252	9.7%
Cystadenocarcinoma, NOS (8440,8450)	182	0.7%	148	0.7%	21	1.3%	-	-	-	-	-	-
Serous cystadenocarcinoma (8441)	2,312	9.5%	2,006	9.6%	115	7.0%	173	10.5%	-	-	192	7.4%
Papillary serous cystadenocarcinoma (8460-8462)	7,690	31.5%	6,853	32.8%	427	26.0%	353	21.5%	28	26.9%	731	28.1%
Mucinous cystadenocarcinoma (8470-8473)	638	2.6%	519	2.5%	38	2.3%	70	4.3%	-	-	96	3.7%
Mucinous adenocarcinoma (8480,8482)	871	3.6%	696	3.3%	84	5.1%	76	4.6%	-	-	107	4.1%
Mucin-producing adenocarcinoma(8481)	94	0.4%	80	0.4%	-	-	-	-	-	-	-	-
Other	1,018	4.2%	879	4.2%	47	2.9%	87	5.3%	-	-	107	4.1%
Other specific carcinomas ^e	526	2.2%	410	2.0%	86	5.2%	26	1.6%	-	-	83	3.2%
Stromal cell tumor (8620-8631,8650)	309	1.3%	225	1.1%	67	4.1%	-	-	-	-	52	2.0%
Other	178	0.7%	152	0.7%	-	-	-	-	-	-	28	1.1%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	1,069	4.4%	913	4.4%	80	4.9%	55	3.3%	-	-	124	4.8%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^d Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941, 9110.

^e Other specific carcinomas includes histologies 8011-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8247-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

Table XXI-13 - continued

OVARY CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Females by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9141-9340,9540-9582)	81	0.3%	61	0.3%	18	1.1%	-	-	-	-	-	-
Other specific types (8240-8246,8720-8790,8930-8936,8950-8983,9000-9030,9060-9105,9350-9364,9380-9513,9530-9539)	1,583	6.5%	1,313	6.3%	123	7.5%	131	8.0%	-	-	306	11.8%
Mullerian mixed tumor (8950-8951,8980)	677	2.8%	596	2.8%	36	2.2%	40	2.4%	-	-	63	2.4%
Teratoma, malignant (9080-9085,9102)	336	1.4%	251	1.2%	37	2.3%	44	2.7%	-	-	108	4.2%
Other	570	2.3%	466	2.2%	50	3.0%	47	2.9%	-	-	135	5.2%
Unspecified (8000-8005)	191	0.8%	163	0.8%	19	1.2%	-	-	-	-	32	1.2%
Total ^c	24,432	100.0%	20,914	100.0%	1,643	100.0%	1,643	100.0%	104	100.0%	2,602	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Total includes carcinoma cases from the previous page.

Table XXIV-17

STOMACH CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	26,270	95.1%	19,098	95.3%	3,134	92.0%	3,705	96.0%	192	99.5%	4,231	97.1%
Epidermoid carcinoma ^c	217	0.8%	160	0.8%	40	1.2%	-	-	-	-	-	-
(8051-8131)												
Squamous cell carcinoma	213	0.8%	158	0.8%	39	1.1%	-	-	-	-	-	-
(8070-8078,8083-8084)												
Adenocarcinoma	24,091	87.2%	17,407	86.9%	2,855	83.8%	3,541	91.7%	172	89.1%	3,893	89.3%
(8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)												
Adenocarcinoma, NOS	13,939	50.4%	10,419	52.0%	1,724	50.6%	1,635	42.4%	106	54.9%	1,975	45.3%
(8140)												
Adenocarcinoma, intestinal type (8144)	2,109	7.6%	1,218	6.1%	266	7.8%	603	15.6%	-	-	321	7.4%
Carcinoma, diffuse type (8145)	733	2.7%	435	2.2%	75	2.2%	214	5.5%	-	-	156	3.6%
Linitus plastica (8142)	401	1.5%	309	1.5%	35	1.0%	50	1.3%	-	-	100	2.3%
Mucinous adenocarcinoma	486	1.8%	360	1.8%	57	1.7%	59	1.5%	-	-	62	1.4%
(8470-8473,8480,8482)												
Mucin-producing adenocarcinoma (8481)	337	1.2%	258	1.3%	49	1.4%	23	0.6%	-	-	44	1.0%
Signet ring adenocarcinoma (8490)	4,962	18.0%	3,619	18.1%	509	14.9%	773	20.0%	30	15.5%	1,039	23.8%
Other adenocarcinomas ^d	1,124	4.1%	789	3.9%	140	4.1%	184	4.8%	-	-	196	4.5%
Other specific carcinomas	1,258	4.6%	1,010	5.0%	148	4.3%	71	1.8%	-	-	208	4.8%
(8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)												
Unspecified, Carcinoma, NOS	704	2.5%	521	2.6%	91	2.7%	78	2.0%	-	-	116	2.7%
(8010-8011,8020-8022)												

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^d Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

Table XXIV-17 - continued

STOMACH CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	100	0.4%	80	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,134	4.1%	753	3.8%	239	7.0%	135	3.5%	-	-	96	2.2%
Unspecified (8000-8005)	134	0.5%	99	0.5%	21	0.6%	-	-	-	-	19	0.4%
Total ^c	27,638	100.0%	20,030	100.0%	3,407	100.0%	3,860	100.0%	193	100.0%	4,359	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^c Total includes carcinoma cases from the previous page.

Table XXVI-17

THYROID CANCER(Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		API		AI/AN		Hispanic ^b	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	33,656	99.8%	27,993	99.8%	1,995	99.7%	3,121	99.9%	147	99.3%	4,632	99.7%
Epidermoid carcinoma ^c (8051-8131)	46	0.1%	37	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^d	32,466	96.2%	26,995	96.2%	1,905	95.2%	3,043	97.4%	144	97.3%	4,497	96.8%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	28,669	85.0%	23,898	85.2%	1,576	78.7%	2,728	87.3%	129	87.2%	4,079	87.8%
Follicular carcinoma (8330-8332,8335)	2,247	6.7%	1,785	6.4%	223	11.1%	207	6.6%	-	-	247	5.3%
Oxyphilic (8290)	1,147	3.4%	973	3.5%	85	4.2%	69	2.2%	-	-	120	2.6%
Other specific carcinomas ^e	561	1.7%	490	1.7%	38	1.9%	23	0.7%	-	-	67	1.4%
Medullary carcinoma (8510,8511)	526	1.6%	461	1.6%	35	1.7%	21	0.7%	-	-	61	1.3%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	583	1.7%	471	1.7%	49	2.4%	50	1.6%	-	-	64	1.4%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	367	1.1%	300	1.1%	30	1.5%	33	1.1%	-	-	35	0.8%
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^f	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	65	0.2%	52	0.2%	-	-	-	-	-	-	-	-
Total	33,737	100.0%	28,058	100.0%	2,002	100.0%	3,125	100.0%	148	100.0%	4,645	100.0%

Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). Percents may not sum to 100 due to rounding.

- Statistic not shown due to fewer than 16 cases during the time period.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^c Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry and Kentucky.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other specific carcinomas include histologies 8013-8015, 8030-8046, 8150-8155, 8170-8171, 8230-8249, 8510-8512, 8561-8562, 8575, 8580-8671.

Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.